FDA Announces Guidance on Waiver of Bioavailability and Bioequivalence Studies for Immediate Release Medications

Summary

The FDA has released a guidance document that provides recommendations for sponsors of new drug applications to request a waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms, based on a biopharmaceutics classification system.